Pharma's Top 10 Blockbuster Drugs

Welcome to FiercePharma's look at the bestselling drugs of 2009. With the help of EvaluatePharma and PriceWaterhouse Coopers, we've identified a mix of old standbys and disease-altering biologics that make up this year's top 10 list. Some brands--such as Lipitor, Plavix, Advair--will be facing serious generic competition in the near future, while the harder-to-copy biologics are, for the time being, protected from copycats. In the coming years, EvaluatePharma predicts the top 10 list will be dominated by biologics as more small molecules go off-patent. Two top-selling mainstays, AstraZeneca's Nexium and Amgen's Epogen/Procrit, are absent from this year's list; Humira and Seroquel have taken their place. Click here to begin the slideshow ->

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.